1. Generics Bulletin

Towa to proactively expand

Entering new markets, including the US, through partnerships forms a key part of Towa Pharmaceutical’s ‘Proactive’ medium-term business plan. Editor Aidan Fry examines the Japanese generics specialist’s growth strategy.

As Japan’s generics market progresses towards maturity and the government’s goal of 80% generic penetration of the country’s off-patent drugs market by September 2020, several of the local industry’s leading lights have looked to North America for further growth. Nichi-Iko led the way two years ago by announcing its US$736 million acquisition of US injectables specialist Sagent (Generics bulletin, 22 July 2016, page 1). Sawai then completed its takeover of Upsher-Smith’s generics operation midway through last year (Generics bulletin, 9 June 2017, page 3).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Generics Bulletin

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.

How To Make The Most Of Your GGB Awards Entries

 
• By Dave Wallace

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

Denosumab Race Heats Up In Europe With Eight More Nods

 
• By Dave Wallace

Denosumab competition is heating up in Europe, with four more companies this month gaining EMA endorsements for their Prolia and Xgeva biosimilar rivals.